<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2021-6-132-138</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-1718</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL OBSERVATIONS</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ НАБЛЮДЕНИЯ</subject></subj-group></article-categories><title-group><article-title>Treatment of noncognitive neuropsychiatric disorders in Alzheimer's disease</article-title><trans-title-group xml:lang="ru"><trans-title>Терапия некогнитивных нервно-психических расстройств при болезни Альцгеймера</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9467-6244</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Локшина</surname><given-names>А. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Lokshina</surname><given-names>A. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p> Кафедра нервных болезней и нейрохирургии </p><p>Россия, 119991, Москва, ул. Россолимо, 11, стр. 1 </p></bio><bio xml:lang="en"><p> Department of Nervous System Diseases and Neurosurgery</p><p>11, Rossolimo St., Build. 1, Moscow 119021, Russia </p></bio><email xlink:type="simple">aloksh@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2424-3245</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гришина</surname><given-names>Д. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Grishina</surname><given-names>D. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p> Кафедра нервных болезней и нейрохирургии </p><p>Россия, 119991, Москва, ул. Россолимо, 11, стр. 1 </p></bio><bio xml:lang="en"><p> Department of Nervous System Diseases and Neurosurgery</p><p>11, Rossolimo St., Build. 1, Moscow 119021, Russia </p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Институт клинической медицины им. Н.В. Склифосовского ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.V. Sklifosovsky Institut of Clinical Medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>16</day><month>12</month><year>2021</year></pub-date><volume>13</volume><issue>6</issue><fpage>132</fpage><lpage>138</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Lokshina A.B., Grishina D.A., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Локшина А.Б., Гришина Д.А.</copyright-holder><copyright-holder xml:lang="en">Lokshina A.B., Grishina D.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/1718">https://nnp.ima-press.net/nnp/article/view/1718</self-uri><abstract><p>Alzheimer's disease (AD) is the most common neurodegenerative disease, which is caused by cerebral amyloidosis. Noncognitive neuropsychiatric disorders (NСNPDs) include emotional, behavioral disorders, as well as psychotic symptoms. NСNPDs are almost an obligatory manifestation of this disease, accompany cognitive impairment and are detected at all stages of the disease – from preclinical to the severe dementia stage. As an example, we present a case report of a female patient with mild dementia in AD in whom Akatinol memantine administration resulted in the stabilization of a cognitive defect within one year and a decrease in the severity of emotional and behavioral disorders. The article discusses the indications and contraindications for antipsychotic administration in this disease, NСNPDs treatment in AD, which includes nonpharmacological and pharmacological methods. Accurate analysis of NСNPDs allows to predict the disease course, optimize the treatment, and thereby improve the quality of life of the patient and his relatives and caregivers.</p></abstract><trans-abstract xml:lang="ru"><p>Болезнь Альцгеймера (БА) является самым частым дегенеративным заболеванием головного мозга, в основе которого лежит церебральный амилоидоз. Некогнитивные нервно-психические расстройства (ННПР) – эмоциональные, поведенческие нарушения, а также психотические симптомы. ННПР встречаются при этом заболевании практически всегда, сопровождают нарушения когнитивных функций и выявляются на всех стадиях развития болезни – от доклинической до стадии тяжелой деменции. На примере клинического наблюдения пациентки с легкой деменцией при БА показаны стабилизация когнитивного дефекта в течение одного года и уменьшение выраженности эмоциональных и поведенческих расстройств на фоне приема препарата акатинол мемантин. Рассмотрены показания и противопоказания к приему антипсихотических препаратов при этом заболевании, вопросы терапии ННПР при БА, которая включает в себя как немедикаментозные, так и лекарственные методы. Точный анализ ННПР позволяет прогнозировать течение заболевания, оптимизировать лечение и тем самым улучшать качество жизни пациента, а также его родственников и ухаживающих лиц.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>болезнь Альцгеймера</kwd><kwd>когнитивные нарушения</kwd><kwd>некогнитивные нервно-психические расстройства</kwd><kwd>деменция</kwd><kwd>акатинол мемантин</kwd><kwd>бензодиазепины</kwd><kwd>антипсихотические препараты</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Alzheimer’s disease</kwd><kwd>cognitive impairment</kwd><kwd>noncognitive neuropsychiatric disorders</kwd><kwd>dementia</kwd><kwd>akatinol memantine</kwd><kwd>benzodiazepines</kwd><kwd>antipsychotic drugs.</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Статья спонсируется компанией «Мерц».</funding-statement><funding-statement xml:lang="en">This article has been supported by «Merz».</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Парфенов ВА, Захаров ВВ, Преображенская ИС. Когнитивные расстройства. Москва: Ремедиум; 2014. 192 с.</mixed-citation><mixed-citation xml:lang="en">Parfenov VA, Zaharov VV, Preobrazenskaya IS. Kognitivnyye rasstroystva [Cognitive impairment]. Moscow; 2014. 192 p. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Яхно НН, Захаров ВВ, Локшина АБ и др. Деменции: Руководство для врачей. 3-е изд. Москва: Медпресс-информ; 2011. С. 17-28. Доступно по ссылке: https://www.03book.ru/upload/iblock/987/415_Demencija_Jahno.pdf (дата обращения 24.02.2021).</mixed-citation><mixed-citation xml:lang="en">Yakhno NN, Zakharov VV, Lokshina AB, et al. Dementsii: Rukovodstvo dlya vrachey [Dementia. Guidance for doctors]. Moscow: Medpressinform; 2011. P. 17-28. Available from: https://www.03book.ru/upload/iblock/987/415_Demencija_Jahno.pdf (accessed 24.02.2021) (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Парфенов ВА. Болезнь Альцгеймера: ошибки ведения пациентов. Медицинский совет. 2020;(19):23-8. doi: 10.21518/2079-701X-2020-19-23-28</mixed-citation><mixed-citation xml:lang="en">Parfenov VA. Alzheimer’s disease: clinical management errors. Meditsinskiy sovet = Medical Council. 2020;(19):23-8. doi: 10.21518/2079-701X-2020-19-23-28 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">2016 Alzheimer's disease facts and figures. Alzheimer's Association. Alzheimers Dement. 2016;12(4):459-509. doi: 10.1016/j.jalz.2016.03.001</mixed-citation><mixed-citation xml:lang="en">2016 Alzheimer's disease facts and figures. Alzheimer's Association. Alzheimers Dement. 2016;12(4):459-509. doi: 10.1016/j.jalz.2016.03.001</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Germain S, Adam S, Olivier C, et al. Does cognitive impairment influence burden in caregivers of patients with Alzheimer's disease? J Alzheimers Dis. 2009;17(1):105-14. doi: 10.3233/JAD-2009-1016</mixed-citation><mixed-citation xml:lang="en">Germain S, Adam S, Olivier C, et al. Does cognitive impairment influence burden in caregivers of patients with Alzheimer's disease? J Alzheimers Dis. 2009;17(1):105-14. doi: 10.3233/JAD-2009-1016</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Eikelboom WS, van den Berg E, Singleton EH, et al. Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum: Cross-sectional and Longitudinal Associations. Neurology. 2021 Sep 28;97(13):e1276-e1287. doi: 10.1212/WNL.0000000000012598. Epub 2021 Aug 19.</mixed-citation><mixed-citation xml:lang="en">Eikelboom WS, van den Berg E, Singleton EH, et al. Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum: Cross-sectional and Longitudinal Associations. Neurology. 2021 Sep 28;97(13):e1276-e1287. doi: 10.1212/WNL.0000000000012598. Epub 2021 Aug 19.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao QF, Tan L, Wang HF, et al. The prevalence of neuropsychiatric symptoms in Alzheimer's disease: Systematic review and meta-analysis. J Affect Disord. 2016 Jan 15;190:264-71. doi: 10.1016/j.jad.2015.09.069. Epub 2015 Oct 24.</mixed-citation><mixed-citation xml:lang="en">Zhao QF, Tan L, Wang HF, et al. The prevalence of neuropsychiatric symptoms in Alzheimer's disease: Systematic review and meta-analysis. J Affect Disord. 2016 Jan 15;190:264-71. doi: 10.1016/j.jad.2015.09.069. Epub 2015 Oct 24.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Chen Y, Dang M, Zhang Z. Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer's disease: a systematic review of symptom-general and -specific lesion patterns. Mol Neurodegener. 2021 Jun 7;16(1):38. doi: 10.1186/s13024-021-00456-1</mixed-citation><mixed-citation xml:lang="en">Chen Y, Dang M, Zhang Z. Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer's disease: a systematic review of symptom-general and -specific lesion patterns. Mol Neurodegener. 2021 Jun 7;16(1):38. doi: 10.1186/s13024-021-00456-1</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Murman DL, Chen Q, Powell MC, et al. The incremental direct costs associated with behavioral symptoms in AD. Neurology. 2002 Dec 10;59(11):1721-9. doi: 10.1212/01.wnl.0000036904.73393.e4</mixed-citation><mixed-citation xml:lang="en">Murman DL, Chen Q, Powell MC, et al. The incremental direct costs associated with behavioral symptoms in AD. Neurology. 2002 Dec 10;59(11):1721-9. doi: 10.1212/01.wnl.0000036904.73393.e4</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement. 2011 May;7(3):263-9. doi: 10.1016/j.jalz.2011.03.005. Epub 2011 Apr 21.</mixed-citation><mixed-citation xml:lang="en">McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement. 2011 May;7(3):263-9. doi: 10.1016/j.jalz.2011.03.005. Epub 2011 Apr 21.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging – Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):270-9. doi: 10.1016/j.jalz.2011.03.008. Epub 2011 Apr 21.</mixed-citation><mixed-citation xml:lang="en">Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging – Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):270-9. doi: 10.1016/j.jalz.2011.03.008. Epub 2011 Apr 21.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement. 2011 May;7(3):280-92. doi: 10.1016/j.jalz.2011.03.003. Epub 2011 Apr 21.</mixed-citation><mixed-citation xml:lang="en">Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement. 2011 May;7(3):280-92. doi: 10.1016/j.jalz.2011.03.003. Epub 2011 Apr 21.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Jack CR Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on AgingAlzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011 May;7(3):257-62. doi: 10.1016/j.jalz.2011.03.004. Epub 2011 Apr 21.</mixed-citation><mixed-citation xml:lang="en">Jack CR Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on AgingAlzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011 May;7(3):257-62. doi: 10.1016/j.jalz.2011.03.004. Epub 2011 Apr 21.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Apostolova LG, Cummings JL. Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature. Dement Geriatr Cogn Disord. 2008;25(2):115-26. doi: 10.1159/000112509. Epub 2007 Dec 14.</mixed-citation><mixed-citation xml:lang="en">Apostolova LG, Cummings JL. Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature. Dement Geriatr Cogn Disord. 2008;25(2):115-26. doi: 10.1159/000112509. Epub 2007 Dec 14.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Wiels WA, Wittens MMJ, Zeeuws D, et al. Neuropsychiatric Symptoms in Mild Cognitive Impairment and Dementia Due to AD: Relation With Disease Stage and Cognitive Deficits. Front Psychiatry. 2021 Aug 17;12:707580. doi: 10.3389/fpsyt.2021.707580. eCollection 2021.</mixed-citation><mixed-citation xml:lang="en">Wiels WA, Wittens MMJ, Zeeuws D, et al. Neuropsychiatric Symptoms in Mild Cognitive Impairment and Dementia Due to AD: Relation With Disease Stage and Cognitive Deficits. Front Psychiatry. 2021 Aug 17;12:707580. doi: 10.3389/fpsyt.2021.707580. eCollection 2021.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Moran M, Walsh C, Lynch A, et al. Syndromes of behavioural and psychological symptoms in mild Alzheimer's disease. Int J Geriatr Psychiatry. 2004 Apr;19(4):359-64. doi: 10.1002/gps.1091</mixed-citation><mixed-citation xml:lang="en">Moran M, Walsh C, Lynch A, et al. Syndromes of behavioural and psychological symptoms in mild Alzheimer's disease. Int J Geriatr Psychiatry. 2004 Apr;19(4):359-64. doi: 10.1002/gps.1091</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Defrancesco M, Marksteiner J, Kemmler G, et al. Specific Neuropsychiatric Symptoms Are Associated with Faster Progression in Alzheimer's Disease: Results of the Prospective Dementia Registry (PRODEMAustria). J Alzheimers Dis. 2020;73(1):125-33. doi: 10.3233/JAD-190662</mixed-citation><mixed-citation xml:lang="en">Defrancesco M, Marksteiner J, Kemmler G, et al. Specific Neuropsychiatric Symptoms Are Associated with Faster Progression in Alzheimer's Disease: Results of the Prospective Dementia Registry (PRODEMAustria). J Alzheimers Dis. 2020;73(1):125-33. doi: 10.3233/JAD-190662</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Вознесенская ТГ, Медведева АВ, Яхно НН. Некогнитивные нервно-психические расстройства при болезни Альцгеймера и их коррекция. Неврологический журнал. 2010;15(4):18-24.</mixed-citation><mixed-citation xml:lang="en">Voznesenskaya TG, Medvedeva AV, Yakhno NN. Non-cognitive neuropsychiatric disorders in Alzheimer's disease and it’s correction. Nevrologicheskiy zhurnal. 2010;15(4):18-24 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Rosenberg PB, Nowrangi MA, Lyketsos CG. Neuropsychiatric symptoms in Alzheimer's disease: What might be associated brain circuits? Mol Aspects Med. Jun-Oct 2015;43-44:25-37. doi: 10.1016/j.mam.2015.05.005. Epub 2015 Jun 3.</mixed-citation><mixed-citation xml:lang="en">Rosenberg PB, Nowrangi MA, Lyketsos CG. Neuropsychiatric symptoms in Alzheimer's disease: What might be associated brain circuits? Mol Aspects Med. Jun-Oct 2015;43-44:25-37. doi: 10.1016/j.mam.2015.05.005. Epub 2015 Jun 3.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kales H, Gitlin L, Lyketsos C. Assessmentand management of behavioral and psychological symptoms of dementia. BMJ. 2015 Mar 2;350:h369. doi: 10.1136/bmj.h369</mixed-citation><mixed-citation xml:lang="en">Kales H, Gitlin L, Lyketsos C. Assessmentand management of behavioral and psychological symptoms of dementia. BMJ. 2015 Mar 2;350:h369. doi: 10.1136/bmj.h369</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Senanarong V, Cummings JL, Fairbanks L, et al. Agitation in Alzheimer's disease is a manifestation of frontal lobe dysfunction. Dement Geriatr Cogn Disord. 2004;17(1-2):14-20. doi: 10.1159/000074080. Epub 2003 Oct 13.</mixed-citation><mixed-citation xml:lang="en">Senanarong V, Cummings JL, Fairbanks L, et al. Agitation in Alzheimer's disease is a manifestation of frontal lobe dysfunction. Dement Geriatr Cogn Disord. 2004;17(1-2):14-20. doi: 10.1159/000074080. Epub 2003 Oct 13.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Захаров ВВ, Вознесенская ТГ. Нервнопсихические нарушения: диагностические тесты. 6-е изд. Москва: Медпреcс-информ; 2018. 320 с. Доступно по ссылке: https://static-ru.insales.ru/files/1/4942/10457934/original/nervno_psix_nar.pdf (дата обращения 24.02.2021).</mixed-citation><mixed-citation xml:lang="en">Zakharov VV, Voznesenskaya TG. Neuropsychiatric disorders: diagnostic tests. Moscow: Medpress-inform; 2018. 320 p. Available from: https://static-ru.insales.ru/files/1/4942/10457934/original/nervno_psix_nar.pdf (accessed 24.02.2021) (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994 Dec;44(12):2308-14. doi: 10.1212/wnl.44.12.2308</mixed-citation><mixed-citation xml:lang="en">Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994 Dec;44(12):2308-14. doi: 10.1212/wnl.44.12.2308</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Васенина ЕЕ, Ганькина ОА. Нейропсихиатрические нарушения при деменции: механизмы развития и подходы к коррекции. Журнал неврологии и психиатрии им. С.С. Корсакова. 2017;6(2):58-65. doi: 10.17116/jnevro20171176258-65</mixed-citation><mixed-citation xml:lang="en">Vasenina EE, Gan’kina OA. Neuropsychiatric disorders in dementia: mechanisms and treatment approach. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2017;6(2):58-65. doi: 10.17116/jnevro20171176258-65 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Chalfont G, Milligan C, Simpson J. A mixed methods systematic review of multimodal non-pharmacological interventions to improve cognition for people with dementia. Dementia (London). 2020 May;19(4):1086-130. doi: 10.1177/1471301218795289. Epub 2018 Sep 7.</mixed-citation><mixed-citation xml:lang="en">Chalfont G, Milligan C, Simpson J. A mixed methods systematic review of multimodal non-pharmacological interventions to improve cognition for people with dementia. Dementia (London). 2020 May;19(4):1086-130. doi: 10.1177/1471301218795289. Epub 2018 Sep 7.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Kales H, Kim H, Zivin K, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2012 Jan;169(1):71-9. doi: 10.1176/appi.ajp.2011.11030347. Epub 2011 Oct 31.</mixed-citation><mixed-citation xml:lang="en">Kales H, Kim H, Zivin K, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2012 Jan;169(1):71-9. doi: 10.1176/appi.ajp.2011.11030347. Epub 2011 Oct 31.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients with Dementia. Am J Psychiatry. 2016;173(5):543-6. doi: 10.1176/appi.ajp.2015.173501</mixed-citation><mixed-citation xml:lang="en">Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients with Dementia. Am J Psychiatry. 2016;173(5):543-6. doi: 10.1176/appi.ajp.2015.173501</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Ettcheto M, Olloquequi J, Sanchez-Lopez E, et al. Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer’s Disease Dementia. Front Aging Neurosci. 2020 Jan 8;11:344. doi: 10.3389/fnagi.2019.00344. eCollection 2019.</mixed-citation><mixed-citation xml:lang="en">Ettcheto M, Olloquequi J, Sanchez-Lopez E, et al. Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer’s Disease Dementia. Front Aging Neurosci. 2020 Jan 8;11:344. doi: 10.3389/fnagi.2019.00344. eCollection 2019.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Suzuki Y, Sakakibara M, Shiraishi N, et al. Use of Anti-Dementia Drugs Reduces the Risk of Potentially Inappropriate Medications: A Secondary Analysis of a Nationwide Survey of Prescribing Pharmacies. Dement Geriatr Cogn Disord. 2020;49(5):526-32. doi: 10.1159/000512043. Epub 2020 Dec 4.</mixed-citation><mixed-citation xml:lang="en">Suzuki Y, Sakakibara M, Shiraishi N, et al. Use of Anti-Dementia Drugs Reduces the Risk of Potentially Inappropriate Medications: A Secondary Analysis of a Nationwide Survey of Prescribing Pharmacies. Dement Geriatr Cogn Disord. 2020;49(5):526-32. doi: 10.1159/000512043. Epub 2020 Dec 4.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Колыхалов ИВ. Лечение поведенческих и психотических симптомов болезни Альцгеймера: вклад мемантина. Современная терапия в психиатрии и неврологии. 2013;(3-4):17-20.</mixed-citation><mixed-citation xml:lang="en">Kolykhalov IV. Treatment of behavioral and psychotic symptoms of Alzheimer’s disease: the contribution of memantine. Sovremennaya terapiya v psikhiatrii i nevrologii. 2013;(3-4):17-20 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Francis PT. Altered Glutamate Neurotransmission and Behaviour in Dementia: Evidence from Studies of Memantine. Current Mol Pharmacol. 2009 Jan;2(1):77-82. doi: 10.2174/1874467210902010077</mixed-citation><mixed-citation xml:lang="en">Francis PT. Altered Glutamate Neurotransmission and Behaviour in Dementia: Evidence from Studies of Memantine. Current Mol Pharmacol. 2009 Jan;2(1):77-82. doi: 10.2174/1874467210902010077</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019 Mar 20;3(3):CD003154. doi: 10.1002/14651858.CD003154.pub</mixed-citation><mixed-citation xml:lang="en">McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019 Mar 20;3(3):CD003154. doi: 10.1002/14651858.CD003154.pub</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Tekin S, Mega MS, Masterman DM, et al. Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann Neurol. 2001 Mar;49(3):355-61.</mixed-citation><mixed-citation xml:lang="en">Tekin S, Mega MS, Masterman DM, et al. Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann Neurol. 2001 Mar;49(3):355-61.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Reisberg B, Doody R, Stöffler A, et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003 Apr 3;348(14):1333-41. doi: 10.1056/NEJMoa013128</mixed-citation><mixed-citation xml:lang="en">Reisberg B, Doody R, Stöffler A, et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003 Apr 3;348(14):1333-41. doi: 10.1056/NEJMoa013128</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Cummings JL, Schneider E, Tariot PN, Graham SM. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology. 2006 Jul 11;67(1):57-63. doi: 10.1212/01.wnl.0000223333.42368.f1</mixed-citation><mixed-citation xml:lang="en">Cummings JL, Schneider E, Tariot PN, Graham SM. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology. 2006 Jul 11;67(1):57-63. doi: 10.1212/01.wnl.0000223333.42368.f1</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer’s disease by memantine: a pooled data analysis. Int J Geriatric Psych. 2008 May;23(5):537-45. doi: 10.1002/gps.1949</mixed-citation><mixed-citation xml:lang="en">Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer’s disease by memantine: a pooled data analysis. Int J Geriatric Psych. 2008 May;23(5):537-45. doi: 10.1002/gps.1949</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Kishi T, Matsunaga S, Iwata N. The effects of memantine on behavioral disturbances in patients with Alzheimer's disease: a meta-analysis. Neuropsychiatr Dis Treat. 2017 Jul 20;13:1909-28. doi: 10.2147/NDT.S142839. eCollection 2017.</mixed-citation><mixed-citation xml:lang="en">Kishi T, Matsunaga S, Iwata N. The effects of memantine on behavioral disturbances in patients with Alzheimer's disease: a meta-analysis. Neuropsychiatr Dis Treat. 2017 Jul 20;13:1909-28. doi: 10.2147/NDT.S142839. eCollection 2017.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Преображенская ИС. Антагонисты NMDA-рецепторов в лечении неврологических заболеваний. Неврология, нейропсихиатрия, психосоматика. 2020;12(5):71-7. doi: 10.14412/2074-2711-2020-5-71-77</mixed-citation><mixed-citation xml:lang="en">Preobrazhenskaya IS. NMDA receptor antagonists in the treatment of neurological diseases. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(5):71-7. doi: 10.14412/2074-2711-2020-5-71-77 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Folch J, Busquets O, Ettcheto M, et al. Memantine for the Treatment of Dementia: A Review on its Current and Future Applications. J Alzheimers Dis. 2018;62(3):1223-40. doi: 10.3233/JAD-170672</mixed-citation><mixed-citation xml:lang="en">Folch J, Busquets O, Ettcheto M, et al. Memantine for the Treatment of Dementia: A Review on its Current and Future Applications. J Alzheimers Dis. 2018;62(3):1223-40. doi: 10.3233/JAD-170672</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
